321 related articles for article (PubMed ID: 28385542)
1. Model Systems for Studying the Role of Canalicular Efflux Transporters in Drug-Induced Cholestatic Liver Disease.
Stieger B; Mahdi ZM
J Pharm Sci; 2017 Sep; 106(9):2295-2301. PubMed ID: 28385542
[TBL] [Abstract][Full Text] [Related]
2. Hepatobiliary transporters in drug-induced cholestasis: a perspective on the current identifying tools.
de Lima Toccafondo Vieira M; Tagliati CA
Expert Opin Drug Metab Toxicol; 2014 Apr; 10(4):581-97. PubMed ID: 24588537
[TBL] [Abstract][Full Text] [Related]
3. Drug-induced perturbations of the bile acid pool, cholestasis, and hepatotoxicity: mechanistic considerations beyond the direct inhibition of the bile salt export pump.
Rodrigues AD; Lai Y; Cvijic ME; Elkin LL; Zvyaga T; Soars MG
Drug Metab Dispos; 2014 Apr; 42(4):566-74. PubMed ID: 24115749
[TBL] [Abstract][Full Text] [Related]
4. Development of a mechanistic biokinetic model for hepatic bile acid handling to predict possible cholestatic effects of drugs.
Notenboom S; Weigand KM; Proost JH; van Lipzig MMH; van de Steeg E; van den Broek PHH; Greupink R; Russel FGM; Groothuis GMM
Eur J Pharm Sci; 2018 Mar; 115():175-184. PubMed ID: 29309877
[TBL] [Abstract][Full Text] [Related]
5. The C-DILI™ Assay: An Integrated In Vitro Approach to Predict Cholestatic Hepatotoxicity.
Jackson JP; Brouwer KR
Methods Mol Biol; 2019; 1981():75-85. PubMed ID: 31016648
[TBL] [Abstract][Full Text] [Related]
6. Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714.
Feng B; Xu JJ; Bi YA; Mireles R; Davidson R; Duignan DB; Campbell S; Kostrubsky VE; Dunn MC; Smith AR; Wang HF
Toxicol Sci; 2009 Apr; 108(2):492-500. PubMed ID: 19223659
[TBL] [Abstract][Full Text] [Related]
7. Ticlopidine, a cholestatic liver injury-inducible drug, causes dysfunction of bile formation via diminished biliary secretion of phospholipids: involvement of biliary-excreted glutathione-conjugated ticlopidine metabolites.
Yoshikado T; Takada T; Yamamoto H; Tan JK; Ito K; Santa T; Suzuki H
Mol Pharmacol; 2013 Feb; 83(2):552-62. PubMed ID: 23220748
[TBL] [Abstract][Full Text] [Related]
8. The expression levels of plasma membrane transporters in the cholestatic liver of patients undergoing biliary drainage and their association with the impairment of biliary secretory function.
Shoda J; Kano M; Oda K; Kamiya J; Nimura Y; Suzuki H; Sugiyama Y; Miyazaki H; Todoroki T; Stengelin S; Kramer W; Matsuzaki Y; Tanaka N
Am J Gastroenterol; 2001 Dec; 96(12):3368-78. PubMed ID: 11774951
[TBL] [Abstract][Full Text] [Related]
9. Early Alterations of Bile Canaliculi Dynamics and the Rho Kinase/Myosin Light Chain Kinase Pathway Are Characteristics of Drug-Induced Intrahepatic Cholestasis.
Burbank MG; Burban A; Sharanek A; Weaver RJ; Guguen-Guillouzo C; Guillouzo A
Drug Metab Dispos; 2016 Nov; 44(11):1780-1793. PubMed ID: 27538918
[TBL] [Abstract][Full Text] [Related]
10. Defective canalicular transport and toxicity of dietary ursodeoxycholic acid in the abcb11-/- mouse: transport and gene expression studies.
Wang R; Liu L; Sheps JA; Forrest D; Hofmann AF; Hagey LR; Ling V
Am J Physiol Gastrointest Liver Physiol; 2013 Aug; 305(4):G286-94. PubMed ID: 23764895
[TBL] [Abstract][Full Text] [Related]
11. Effect of a Common Genetic Variant (p.V444A) in the Bile Salt Export Pump on the Inhibition of Bile Acid Transport by Cholestatic Medications.
Ali I; Khalid S; Stieger B; Brouwer KLR
Mol Pharm; 2019 Mar; 16(3):1406-1411. PubMed ID: 30608704
[TBL] [Abstract][Full Text] [Related]
12. In vitro model systems to investigate bile salt export pump (BSEP) activity and drug interactions: A review.
Cheng Y; Woolf TF; Gan J; He K
Chem Biol Interact; 2016 Aug; 255():23-30. PubMed ID: 26683212
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4.
Köck K; Ferslew BC; Netterberg I; Yang K; Urban TJ; Swaan PW; Stewart PW; Brouwer KL
Drug Metab Dispos; 2014 Apr; 42(4):665-74. PubMed ID: 24154606
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular transporters and cholestasis.
Pauli-Magnus C; Meier PJ
J Clin Gastroenterol; 2005 Apr; 39(4 Suppl 2):S103-10. PubMed ID: 15758645
[TBL] [Abstract][Full Text] [Related]
15. Organic solute transporter OSTα/β is overexpressed in nonalcoholic steatohepatitis and modulated by drugs associated with liver injury.
Malinen MM; Ali I; Bezençon J; Beaudoin JJ; Brouwer KLR
Am J Physiol Gastrointest Liver Physiol; 2018 May; 314(5):G597-G609. PubMed ID: 29420067
[TBL] [Abstract][Full Text] [Related]
16. Molecular and Clinical Links between Drug-Induced Cholestasis and Familial Intrahepatic Cholestasis.
Vitale G; Mattiaccio A; Conti A; Berardi S; Vero V; Turco L; Seri M; Morelli MC
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982896
[TBL] [Abstract][Full Text] [Related]
17. Nimesulide and 4'-Hydroxynimesulide as Bile Acid Transporters Inhibitors Are Contributory Factors for Drug-Induced Cholestasis.
Zhou L; Pang X; Jiang J; Zhong D; Chen X
Drug Metab Dispos; 2017 May; 45(5):441-448. PubMed ID: 28202577
[TBL] [Abstract][Full Text] [Related]
18. A Change in Bile Flow: Looking Beyond Transporter Inhibition in the Development of Drug-induced Cholestasis.
Garzel B; Zhang L; Huang SM; Wang H
Curr Drug Metab; 2019; 20(8):621-632. PubMed ID: 31288715
[TBL] [Abstract][Full Text] [Related]
19. BSEP inhibition: in vitro screens to assess cholestatic potential of drugs.
Kis E; Ioja E; Rajnai Z; Jani M; Méhn D; Herédi-Szabó K; Krajcsi P
Toxicol In Vitro; 2012 Dec; 26(8):1294-9. PubMed ID: 22120137
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics of hepatocellular transporters.
Pauli-Magnus C; Meier PJ
Pharmacogenetics; 2003 Apr; 13(4):189-98. PubMed ID: 12668915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
